Genetic polymorphisms to analyze and predict treatment-related adverse effects in children with acute lymphoblastic leukemia
| Project/Area Number |
20790135
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
NAKAMURA Tsutomu Kobe University, 薬学部, 教授 (80379411)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2008: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | オーダーメード医療 / 小児白血病 / 遺伝子多型 |
|---|
| Research Abstract |
Some children with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) experience clinically important treatment-related adverse effects. In the present study, to identify novel potential loci influencing the risk of treatment-related hepatotoxicity during the maintenance phase, a genome-wide genotyping analysis was performed in Japanese children with ALL or LBL. Genome-wide genotyping uncovered a total of 28 candidate SNPs. rs1966862, in Rho GTPase-activating protein 24 (ARHGAP24), was the most significant of the candidates, and the genotypes of rs7403531 (RASGRP1) and some genes were also significantly associated with severe hepatotoxicity. This study suggested rs1966862 (ARHGAP24) and the other SNPs to be predictive factors for drug-induced hepatotoxicity during the maintenance phase in pediatric patients with ALL or LBL.
|
Report
(4 results)
Research Products
(22 results)
